World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
84
Citations
28656
World Ranking
1355
National Ranking
86

Medicine

D-Index
84
Citations
28656
World Ranking
15001
National Ranking
792

Rienk Offringa publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Rienk Offringa sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 241 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Rienk Offringa D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Rienk Offringa sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 84 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Rienk Offringa is affiliated with the German Cancer Research Center in Germany. Their research work spans several intersecting fields, primarily within medicine, immunology and microbiology, and biochemistry, genetics and molecular biology.

The scientist's main fields of study include:

  • Medicine
  • Immunology and Microbiology
  • Biochemistry, Genetics and Molecular Biology

Within these areas, they focus on several subfields such as oncology, immunology, molecular biology, cancer research, and pathology and forensic medicine.

  • Oncology
  • Immunology
  • Molecular Biology
  • Cancer Research
  • Pathology and Forensic Medicine

Major topics within Rienk Offringa's work cover a range of important biomedical research themes:

  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Immune cells in cancer
  • Pancreatic and Hepatic Oncology Research
  • Immunotherapy and Immune Responses

The scientist has published research articles in several prominent venues. Frequent publication outlets include:

  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Regular and Young Investigator Award Abstracts
  • Scientific Reports

Rienk Offringa collaborates regularly with several researchers, including Michael Volkmar, Isabel Poschke, Daniel Baumann, Zibo Meng, and Stefan Zens.

  • Michael Volkmar
  • Isabel Poschke
  • Daniel Baumann
  • Zibo Meng
  • Stefan Zens

Selected recent papers featuring or authored by Rienk Offringa include:

  • The expanding role for small molecules in immuno-oncology, 2022, Nature Reviews Drug Discovery
  • The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients, 2020, Molecular Therapy - Oncolytics
  • The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones, 2020, Clinical Cancer Research
  • Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy, 2020, Nature Communications
  • Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy, 2023, Journal for ImmunoTherapy of Cancer

Best Publications

  • T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

    S. P. Schoenberger;R. E. M. Toes;E. I. H. Van Der Voort;R. Offringa

  • Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

    R. P.M. Sutmuller;L. M. Van Duivenvoorde;A. Van Elsas;T. N.M. Schumacher

  • Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

    Gemma G Kenter;Marij J P Welters;A Rob P M Valentijn;Margriet J G Lowik

  • CD4 T cells and their role in antitumor immune responses.

    René E.M. Toes;Ferry Ossendorp;Rienk Offringa;Cornelis J.M. Melief

  • Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides

    Sander Zwaveling;Sandra C. Ferreira Mota;Jan Nouta;Mark Johnson

  • CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

    Diehl L;den Boer At;Schoenberger Sp;van der Voort Ei

  • The minor histocompatibility antigen HA-1 : A diallelic gene with a single amino acid polymorphism

    J.M.M. den Haan;L.M. Meadows;W. Wang;J. Pool

  • High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

    Sytse J. Piersma;Ekaterina S. Jordanova;Mariëtte I.E. van Poelgeest;Kitty M.C. Kwappenberg

  • Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine Comparison of Prophylaxis and Therapy

    A. Van Elsas;R. P M Sutmuller;A. A. Hurwitz;J. Ziskin

  • Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

    Marij J P Welters;Gemma G Kenter;Sytse J Piersma;Annelies P G Vloon

  • Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

    J. P. Medema;J. de Jong;L. T. C. Peltenburg;E. M. E. Verdegaal

  • Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

    J. P. Medema;J. De Jong;T. Van Hall;C. J. M. Melief

  • Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity

    Gemma G Kenter;Marij J P Welters;A Rob P M Valentijn;Margriet J G Lowik

  • CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis.

    Mary E. Morgan;Roger P. M. Sutmuller;Hendrik J. Witteveen;Leonie M. van Duivenvoorde

  • Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

    R. E. M. Toes;R. Offringa;R. J. J. Blom;C. J. M. Melief

  • Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

    Annemieke de Jong;Mariëtte I. E. van Poelgeest;Jeanette M. van der Hulst;Jan Wouter Drijfhout

  • Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

    W.Martin Kast;Rienk Offringa;Peter J. Peters;Arie C. Voordouw

  • CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity

    Martijn S. Bijker;Susan J. F. van den Eeden;Kees L. Franken;Cornelis J. M. Melief

  • Efficient Identification of Novel HLA-A * 0201-presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen PRAME by Proteasome-mediated Digestion Analysis

    Jan H. Kessler;Nico J. Beekman;Sandra A. Bres-Vloemans;Pauline Verdijk

  • CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

    Geertje J. D. van Mierlo;Annemieke Th. den Boer;Jan Paul Medema;Ellen I. H. van der Voort

Frequent Co-Authors

Cornelis J. M. Melief
Cornelis J. M. Melief ISA Pharmaceuticals (Netherlands)
Sjoerd H. van der Burg
Sjoerd H. van der Burg Leiden University Medical Center
René E. M. Toes
René E. M. Toes Leiden University Medical Center
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
Gemma G. Kenter
Gemma G. Kenter Vrije Universiteit Amsterdam
Ferry Ossendorp
Ferry Ossendorp Leiden University Medical Center
Kees L. M. C. Franken
Kees L. M. C. Franken Leiden University Medical Center
Gert Jan Fleuren
Gert Jan Fleuren Leiden University Medical Center
Marij J. P. Welters
Marij J. P. Welters Leiden University Medical Center
Stephen P. Schoenberger
Stephen P. Schoenberger La Jolla Institute For Allergy & Immunology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, pursuing related nursing degrees can open diverse career pathways in healthcare and research. Many professionals start with a Bachelor of Science in Nursing (BSN), especially those transitioning from other fields. Programs like the best online BSN programs for non nurses offer flexible options for newcomers, enabling them to build a strong clinical foundation while accommodating different schedules.

Accelerated programs are popular among those seeking faster entry into advanced roles. For example, the accelerated FNP track is designed for nurses aiming to become Family Nurse Practitioners quickly, focusing on comprehensive primary care skills. Similarly, those wishing to begin nursing education rapidly can explore accelerated nursing programs near me, which provide streamlined admissions and fast-paced curricula.

For current Nurse Practitioners looking to specialize further, a FNP to Acute Care NP bridge program offers a valuable path to expand expertise into acute care settings. These evolving education options reflect the dynamic nature of healthcare careers linked to Immunology, emphasizing the importance of continuous learning and adaptability.

Best Scientists Citing Rienk Offringa

Trending Scientists

Recently Published Articles